JAZZ Looks 61.2% Overvalued on GF Value™ as Positive Trial Data Boosts Sentiment

gurufocus.com · 2026-08-31

On August 31, 2026, Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) announced encouraging second interim overall survival results from its Phase 3 HERIZON-GEA-01 trial

Read the full story at gurufocus.com →